1 Reduced brain responsiveness to emotional stimuli with

2 escitalopram but not psilocybin therapy for depression

- 3
- 4 Matthew B. Wall^{1,2,3}, Lysia Demetriou^{1,2,4}, Bruna Giribaldi⁵, Leor Roseman⁵, Natalie Ertl^{1,2},
- 5 David Erritzoe⁵, David J. Nutt⁵, Robin L. Carhart-Harris^{5,6}.
- 6
- 7 ¹Invicro London, Hammersmith Hospital, UK
- 8 ²Faculty of Medicine, Imperial College London, UK
- 9 ³Clinical Psychopharmacology Unit, University College London, UK
- 10 ⁴Nuffield Department of Women's and Reproductive Health, University of Oxford
- ⁵Centre for Psychedelic Research, Division of Psychiatry, Department of Brain Sciences,
- 12 Faculty of Medicine, Imperial College London
- 13 ⁶Psychedelics Division, Neuroscape, University of California San Francisco, USA.
- 14
- 15
- 16 Corresponding Author:
- 17 Matthew B. Wall
- 18 <u>matt.wall@invicro.co.uk</u>
- 19
- 20

21 Funding and Disclosures

- 22 This trial was funded by a private donation from the Alexander Mosley Charitable Trust,
- 23 supplemented by Founders of ICL's Centre for Psychedelic Research (CPR)
- 24 (https://www.imperial.ac.uk/psychedelic-research-centre/funding-partners/). Infrastructure
- 25 support was provided by the NIHR Imperial Biomedical Research Centre and the NIHR
- 26 Imperial Clinical Research Facility.
- 27 Authors MBW, LD, and NE's primary employer is Invicro LLC., a contract research
- 28 organization which provides services to the pharmaceutical and biotechnology industries.
- 29 RCH is a scientific advisor to Maya Health, Osmind, Beckley Psytech, Usona Institute,
- 30 Mindstate, Entheos Labs, and TRYP therapeutics. DJN is a scientific advisor to Awakn Life
- 31 Sciences, and Algernon pharmaceuticals, and Psyched Wellness. DE is a scientific advisor to
- 32 Mindstate, Aya Biosciences, and Clerkenwell Health.
- 33

34 Abstract

- 36 Psilocybin therapy is an emerging intervention for depression that may be at least as
- 37 effective as standard first-line treatments i.e., Selective Serotonin Reuptake Inhibitors
- 38 (SSRIs). Here we assess neural responses to emotional faces (fear, happy, and neutral) using
- 39 Blood Oxygen-Level Dependent (BOLD) functional Magnetic Resonance Imaging (fMRI) in
- 40 two groups with major depressive disorder: 1) a 'psilocybin group' that received two dosing
- 41 sessions with 25mg plus six weeks of daily placebo, and 2) an 'escitalopram group' that
- 42 received six weeks of the SSRI escitalopram, plus two dosing sessions with an
- 43 inactive/placebo dose of 1mg psilocybin. Both groups had an equal amount of psychological
- 44 support throughout. An emotional face fMRI paradigm was completed at baseline (pre-
- 45 treatment) and at the six-week post-treatment primary endpoint (three weeks following
- 46 psilocybin dosing sessions). An analysis examining the interaction between patient group
- 47 (psilocybin vs. escitalopram) and time-point (pre- vs. post-treatment) showed a robust
- 48 effect in a distributed network of cortical brain regions. Follow-up analyses showed that
- 49 post-treatment BOLD responses to emotional faces of all types were significantly reduced in
- 50 the escitalopram group, with no change, or even a slight increase, in the psilocybin group.
- 51 Specific analyses of the amygdala showed a reduction of response to fear faces in the
- 52 escitalopram group, but no effects for the psilocybin group. Despite large improvements in
- 53 depressive symptoms in the psilocybin group, psilocybin-therapy had only a minor effect on
- 54 brain responsiveness to emotional stimuli. We suggest that reduced emotional
- responsiveness may be a biomarker of SSRIs' antidepressant action that is not shared by
- 56 psilocybin-therapy.

57 Introduction

58

59 Major Depressive Disorder (MDD) is one of the most prevalent and debilitating psychiatric 60 disorders ¹. Current treatment guidelines suggest psychotherapy for mild depression, with 61 pharmacotherapy or a combination of the two treatments recommended for moderate-to-62 severe cases ². Pharmacotherapy with Selective Serotonin Reuptake Inhibitors (SSRIs) is a 63 popular option. However, SSRIs are only moderately effective, take four to eight weeks to 64 show a meaningful therapeutic response, and have acceptability rates (indexed by 65 treatment discontinuation) comparable with placebo ³, i.e. around 25-30% ⁴.

66

67 A phenomenon commonly referred to as 'emotional blunting' (i.e., a restricted range or

- 68 intensity of emotional experience) has been associated with SSRI use, with one survey
- 69 suggesting a prevalence close to 50% ⁵. Diminished libido and sexual functioning with SSRI
- 70 treatment ^{6,7} and a modest impact on symptoms of anhedonia in depression ⁸ are also
- 71 commonly reported. One potential cause of diminished emotional responsiveness via SSRIs
- 72 may be increased 5-HT activity on inhibitory postsynaptic 5-HT1A receptors in limbic and
- 73 paralimbic circuitry implicated in affective and hedonic functioning ^{9,10}. Specifically,
- 74 decreased amygdala responsiveness to emotional stimuli (i.e. a normalization of responses
- to negative stimuli) has been found in depressed patients soon after beginning a course of
- SSRIs ^{11,12}, and similar effects have been found in healthy subjects with short-term use of
- 77 SSRIs ^{13,14}. This emotional/amygdala blunting has been hypothesized to be central to their
- 78 therapeutic effect ^{15,16}.
- 79

80 Novel treatments for major depression are generating a great deal of interest in psychiatry 81 ^{17,18}. Ketamine has shown potential as a rapid-acting treatment option ¹⁹, and promising results are being seen in small clinical trials assessing psilocybin therapy for depression ^{20–22} 82 83 and depressive symptoms ^{23–25}. Psilocybin is a naturally occurring 'classic' psychedelic which exerts its characteristic subjective effects through direct agonism of the 5-HT2A receptor ²⁶. 84 Acutely a 25mg dose of psilocybin has profound effects on spontaneous brain function ²⁷ 85 86 and longer-term functional brain changes have been reported with this dose of psilocybin in depressed ^{28–30} as well as in healthy individuals ^{31,32}. In clinical use, psilocybin dosing 87 sessions can be combined with psychological therapy and support, before ('preparation' 88 89 sessions), during the dosing sessions, and after ('integration' sessions)³³. 90

91 Emotional face perception paradigms are widely used in human fMRI studies, and

92 particularly in depression research ³⁴. Using this approach in a sample of patients before and

93 one-day after psilocybin therapy for treatment-resistant depression we previously observed

- 94 an increase in BOLD responsiveness to emotional face stimuli in depressed patients³⁵, which
- 95 may reflect early changes in responses to treatment or 'afterglow' phenomena³⁶, i.e., a sub-
- 96 acute life in mood. Despite being directionally opposite to the BOLD-reducing action of SSRIs
- 97 on emotional faces ^{11,12,37}, this finding was predictive of longer-term treatment response ³⁵.

- 98 An extension of this work identified changes in amygdala connectivity that were also
- 99 associated with clinical improvements ³⁸. In contrast to the emotional blunting associated
- 100 with SSRIs, a sense of increased emotional connection is often reported with effective
- 101 psychedelic therapy ³⁹. Thus, a differential effect on emotional functioning between SSRIs
- and psychedelic therapy could explain their contrasting fMRI findings in emotional
- 103 processing paradigms.
- 104
- 105 The aim of the present study was to directly compare the brain effects of the two
- 106 treatments for the first time, in a double-blinded, randomized-controlled trial. We chose
- 107 escitalopram as an active comparator for psilocybin therapy because of its high
- 108 pharmacological selectivity as a 5-HT reuptake inhibitor and good antidepressant
- 109 performance; in terms of both tolerability and efficacy ^{3,40}. Psilocybin therapy was carried
- 110 out in a manner that was generally consistent with previous studies. The clinical procedures
- are detailed below and the clinical findings are fully reported elsewhere ⁴¹. The specific
- 112 emotional facial expression paradigm employed in this study was similar to those used in
- 113 previous work, e.g. ^{11,35}. The main pre-registered hypothesis for this trial was that the two
- 114 treatments would have significantly different effects on brain responsiveness to emotional
- 115 faces (see trial registration under identifier NCT03429075;
- <u>https://clinicaltrials.gov/ct2/show/NCT03429075</u>). This is therefore the first report of the
 primary study outcome.
- 118
- 119

120 Methods

121

122 This study was approved by the Brent Research Ethics Committee, with additional approvals

123 from the UK Medicines & Healthcare products Regulatory Agency, the Health Research

124 Authority, and Imperial College London. MRI data collection, drug storage, and dispensing

125 took place at Invicro LLC, Hammersmith Hospital, London. All subjects gave written

126 informed consent, and the trial was conducted under the principles of Good Clinical

- 127 Practice.
- 128

129 Design

130 The full clinical study procedure is reported in ⁴¹. This was a phase II, double-blinded,

- 131 randomized, controlled experimental medicine trial. MRI scanning was done prior to any
- 132 therapeutic intervention (baseline) and six weeks and one day after the first dosing day. For
- 133 the psilocybin group, they received 2 x 25mg doses of psilocybin, three weeks apart. The

134 post-treatment MR scan occurred three weeks after the second 25mg dose. After the first of

- the two dosing sessions, patients in the psilocybin group were provided with a bottle of
- 136 capsules containing microcrystalline cellulose (i.e. inert placebo capsules) and instructed to
- take one per day for the next three weeks and two per day for the final three weeks until
- 138 scan visit two, which was the primary endpoint. Subjects in the escitalopram group received
- a 1mg dose of psilocybin on each of the two dosing visits (also three weeks apart); 1mg has
- 140 negligible subjective effects and therefore served as a control procedure/placebo. These
- 141 subjects were provided with encapsulated escitalopram (10mg capsules) and were
- instructed to take one capsule (10mg escitalopram) daily for the first three weeks, and two
- 143 capsules (20mg) daily for the final three weeks. Scan visit two occurred on the day of the
- 144 final capsule ingestion at the approximate time of peak plasma concentration, implying both
- steady state and acute presence of escitalopram for the escitalopram group.
- 146

147 Clinical scales

148 The primary pre-registered (<u>https://clinicaltrials.gov/ct2/show/NCT03429075</u>) clinical

149 outcome was the Quick Inventory of Depression Score (QIDS-SR16) ⁴². Additional measures

used were the Beck Depression Inventory (BDI)⁴³, the Warwick-Edinburgh Mental Well-

151 being Scale (WEMWBS) for assessment of well-being ⁴⁴, the Snaith-Hamilton Pleasure Scale

- 152 (SHAPS) ⁴⁵ for assessment of anhedonia, the Laukes Emotional Intensity Scale (LEIS) ⁶ for
- assessment of emotional function, and the PRSexDQ ⁴⁶ for assessment of changes to sexual
- 154 function.
- 155

156 Participants and Recruitment

157 For full details of the recruitment and screening procedures see ⁴¹. Participants were

158 recruited using trial networks, social media, and other sources, via a recruitment website

159 (<u>https://www.imperial.ac.uk/psychedelic-research-centre</u>). Volunteers emailed the

160 recruitment coordinator, so all recruited participants were self-referred. There followed a

multi-step screening process involving telephone and video calls, and in-person sessionswith a trial psychiatrist.

163

164 Inclusion criteria were: a score of at least 17 (indicating moderate-to-severe MDD) on the

- 165 HAM-D-17 assessments which were performed on the video call, confirmation of a diagnosis
- 166 of depression and a satisfactory medical history (obtained from the patient's general
- 167 physician), willingness to withdraw completely from psychiatric medication (at least two
- 168 weeks) and psychotherapy (at least three weeks) before starting the trial, age 18-80 years,
- and sufficient competence with English. The main exclusion criteria were a history of certain
- 170 exclusory mental or physical health conditions (both physician-assessed), pregnancy,
- 171 previous courses of escitalopram, and drug or alcohol dependence.
- 172
- 173 Thirty patients were randomized to the psilocybin arm of the study, and 29 were
- 174 randomized to the escitalopram arm. However, four patients in the escitalopram arm
- discontinued treatment due to side effects and were therefore excluded in the present
- analyses. A further five subjects in the escitalopram arm did not complete the second MRI
- visit because of Covid-19 lockdowns in the UK in March/April 2020. Four subjects in the
- psilocybin arm also did not complete their second MRI scanning session also because of
- 179 Covid-19 lockdowns. After the end of the trial, it was revealed that one subject in the
- 180 psilocybin arm had been using cannabis regularly throughout the trial, so their data was also
- 181 excluded. Consequently, there were N=21 subjects available for analysis in the escitalopram
- arm of the study, and N=25 in the psilocybin arm. See figure 1 for the full recruitment flowdiagram.
- 184



185 186

Figure 1. Recruitment flow diagram for the study.

187

188 Task and image acquisition

189 The fMRI task involved stimuli with three facial expressions: fear, happy, and neutral. These were selected from the Karolinska Directed Emotional Faces set ⁴⁷ and presented in blocks 190 191 of five images of the same type, with each image on-screen for 3s. Rest/baseline blocks 192 were also included, which displayed a small fixation cross at the center of the screen. There 193 were eight repeats of each block type presented in a pre-determined pseudo-random order, 194 and 32 blocks in total (eight each of fear, happy, neutral, and rest/baseline). The total task 195 time was eight minutes, plus a 10s buffer period at the end of the task to ensure the last 196 response was fully captured. Two different pseudo-random orders of block presentation 197 were used, and subjects saw one order on the first visit and a different order on the second 198 visit. Patients passively viewed the faces.

- 200 Data was acquired using a Siemens TIM Trio 3 Tesla MRI scanner (Siemens, Erlangen),
- 201 equipped with a 32-channel phased-array head-coil. Anatomical images were acquired using
- 202 the recommended parameters for MPRAGE by the ADNI-GO project 48 : TE = 2.98ms, TR =
- 203 2300ms, 160 sagittal slices, 256x256 in-plane FOV, flip angle = 9°, 1mm isotropic voxels.

204 The functional (Echo-Planar-Imaging) acquisition was based on the multiband EPI WIP v012b

205 provided by the University of Minnesota ^{49–51} using a multiband acceleration factor of 2, and

a slice acceleration (GRAPPA) factor of 2 (TR=1250ms, TE=30ms, 44 slices, 3mm isotropic

voxels, FOV = 192x192mm, flip angle = 70°, bandwidth = 2232Hz/pixel, 392 volumes

acquired). This was based on sequences previously tested and validated by ⁵².

209

210 Data analysis

Analysis was conducted using FSL version 5⁵³. Processing of the anatomical data used the fsl_anat script, which performs a number of processes including inhomogeneity correction and brain extraction using BET (Brain Extraction Tool). Pre-processing of the functional data included head-motion correction, smoothing (6 mm), registration to a standard template (MNI152) using a two-step registration using the subjects' anatomical scans, and high-pass filtering (0.01 Hz).

217

For the first-level analyses, a general linear model contained regressors derived from the
occurrence of the stimuli in three (fear, happy, and neutral face blocks) separate regressors.

220 These stimulus-related time-series were convolved with a standard Gamma function to

221 model the hemodynamic response. An extended set of 24 head-motion regressors were also

included as confounds, which included temporal derivatives and quadratic functions derived

from the raw head-motion parameters. Modelling used FSL's FILM (FMRIB's Improved

Linear Model) for pre-whitening and autocorrelation correction. Contrasts were computed that compared each stimulus condition with the fixation cross baseline condition, as well as

225 that compared each stimulus condition with the fixation cross baseline condition, as wer as

a summary contrast that modelled all stimulus conditions relative to the fixation crossbaseline.

228

229 To visualize treatment effects, mid-level, fixed-effects, within-subjects analyses were used 230 to generate comparisons between pre- and post-intervention visits for each subject. Group 231 analyses were random effects (FLAME-1) models, with statistical maps thresholded at Z =232 2.3, and p < 0.05 (cluster corrected). Mean analyses including data from all subjects and all 233 visits were generated to verify the success of the task paradigm in producing an expected 234 pattern of brain activation, and the general acquisition and analysis procedures (see 235 supplementary material for results). Between-subjects group-level analyses then used the results of the mid-level analyses for a comparison between the two treatment groups 236 237 (psilocybin vs. escitalopram). These comparisons modelled both the difference between 238 groups, and the difference between study visits, and therefore test an interaction effect. 239 Data were extracted from functional clusters/maps in these group-level analyses and plotted to visualize the precise pattern of effects across the task conditions, visits, and drug 240 241 treatment groups. Additionally, group-level analyses of pre-vs. post-treatment effects were also performed with an anatomical amygdala mask, derived from the Harvard-Oxford sub-242 243 cortical atlas, provided with FSL. The rationale for this analysis was based on previous work 244 showing that amygdala connectivity and responsiveness to emotional stimuli can be

- specifically affected by psilocybin therapy ^{35,38} and that it is also a region of interest in
- 246 depression research ¹⁰. Finally, a control analysis was performed that compared the pre-
- 247 therapy (baseline) scans of the two treatment groups, to examine any potential baseline
- 248 differences between the two groups.
- 249
- 250 Additional exploratory analyses were conducted to examine the relationship between
- 251 measures of clinical outcomes, and the BOLD activation data, using Pearson's correlations
- and moderation analyses to examine the specific relationships between clinical depression
- 253 outcomes, BOLD activation data, and a subjective measure of emotional function.

254 Results

255

256 Demographics

257

258 Demographic and selected clinical (baseline, pre-treatment) information for this sample are

shown in table 1. There were no significant differences at baseline between the two groups

260 on any demographic or clinical measure except for the QIDS-SR-16 score, where the

- 261 escitalopram group were somewhat higher.
- 262

2-60) 42.8±11.7(21-64)	t(44)=-1.06, p = 0.294
9 (36)	$\chi^2(1) = 0.287,$ p = 0.592
24 (96)	$\chi^2(1) = 2.67,$ p = 0.102
16 (64)	w ² (2) = 2 FF
7 (28)	$\chi^2(2) = 3.55,$
2 (8)	ρ = 0.471
19 (76)	$\chi^2(1) = 0.12,$ p = 0.725
-30) 4.8±5.8 (0-20)	t(44)=-1.73, p = 0.090
17 (68)	$\chi^2(1) = 0.063,$ p = 0.801
10 (40)	$\chi^2(1) = 0.00,$ p = 1.0
5-46) 21.3±11.0(3-44)	t(44)=-1.84, p = 0.08
0-5) 2.2±1.68 (0-6)	t(44)=-0.505, p = 0.616
23 (92)	$\chi^2(1) = 0.033,$ p = 0.855
22) 13.9±3.4 (7-19)	t(44)=2.128, p = 0.039
0-38) 28.7±6.6 (16-41)	t(44)=0.34, p = 0.735
	2-60) $42.8\pm11.7(21-64)$ 2-60)9 (36)9 (36)24 (96)24 (96)16 (64)7 (28)2 (8)2 (8)19 (76)-30) 4.8 ± 5.8 (0-20)-30) 4.8 ± 5.8 (0-20)-30) 4.8 ± 5.8 (0-20)-30) $21.3\pm1.0(3-44)$ 2-5) 2.2 ± 1.68 (0-6)23 (92)-22) 13.9 ± 3.4 (7-19)2-38) 28.7 ± 6.6 (16-41)

263Table 1. Demographic information and selected baseline clinical scores for the264sample. Pre-treatment baseline was 7-10 days before dosing day 1. All inferential265statistics in the third column are non-significant (at an alpha value of p < 0.05) except266the QIDS-SR-16 baseline score.

267	
268	Clinical data

269

The full clinical results from the entire cohort are presented in ⁴¹, however, selected clinical 270 271 data from the restricted cohort of n = 45 that completed the MRI scanning sessions, after 272 exclusions, is presented here (baseline to six week timepoints). For the primary outcome 273 measure (QIDS SR-16) a mixed-effects analysis with one between-groups factor (treatment) 274 and one within-subjects factor (time) showed a significant main effect of treatment group 275 (F[1,44] = 11.76, p = 0.0013) and time (F[6,251] = 26.36, p < 0.0001), but no significant interaction (figure 2A). A similar analysis was used for Beck Depression Inventory (BDI) 276 277 scores, which also showed significant main effects of time (F[3,113] = 55.89, p < 0.0001), 278 time (F[1,44] = 8.73, p = 0.005), and a significant interaction (F[3,127] = 6.49, p = 0.0004), 279 suggesting a significantly greater decrease in BDI scores in the psilocybin group (figure 2B). 280 281 The same analysis model applied to well-being (WEMWBS) data showed a significant main 282 effect of time (F[2,92) = 20.93, p < 0.0001), a significant main effect of treatment (F[1,44) = 283 12.11, p = 0.0011) and a significant interaction between the two factors (F[3,127) = 4.97, p =284 0.0027). These results suggest significantly greater improvement in well-being scores in the psilocybin treatment group (see figure 2C). A two-way ANOVA analysis of scores on the 285 286 Snaith Hamilton Anhedonia Pleasure Scale (SHAPS) showed no main effect of treatment group (F[1,44) = 2.13, p = 0.15), but a significant effect of pre- vs. post-treatment (F[1,44) = 287 79.89, p < 0.0001), and a significant interaction (F[1,44) = 7.34, p = 0.0096), again suggesting 288 289 greater improvement in anhedonia in the psilocybin group (figure 2D). The change (pre-vs. 290 post-treatment) in scores on perceived emotional responsiveness or intensity (LEIS) were 291 analysed using an unpaired t-test, and showed a significant difference between the groups 292 (t[44] = 5.27, p < 0.0001), i.e., there was a relative decrease in emotional-intensity in the 293 escitalopram group and a relative increase in the psilocybin group (figure 2E). Finally, 294 change scores on the Psychotropic-Related Sexual Dysfunction Questionnaire (PRSexDQ) 295 were also significantly different between the two treatment groups (t[44] = 3.08, p = 296 0.0036) in this restricted cohort (figure 2F). 297



298 299

Figure 2. Selected clinical data from the fMRI sub-sample analyzed here. Error bars 300 301 are standard errors. A: Significant interaction between the treatment groups and time on Beck Depression Inventory (BDI) scores, * p = 0.0002. B. Significant main 302 effect of treatment on the Quick Inventory of Depressive Symptoms (QIDS), * p =303 0.002. C: Significant differences between the treatment groups on the Warwick-304 Edinburgh Mental Well-being Scale (WEMWBS), * p = 0.0031. D: Significant 305 differences between the treatment groups on the Snaith Hamilton Anhedonia 306 307 Pleasure Scale (SHAPS), * p = 0.014. E: Significant differences between the treatment 308 groups on change (pre-vs. post-treatment) scores on the Laukes Emotional Intensity

- Scale (LEIS), * p < 0.0001). F: Significant differences between the treatment groups
 on the Psychotropic-Related Sexual Dysfunction Questionnaire (PRSexDQ). * p =
 0.0036. Note, higher scores on the PRSexDQ reflect greater sexual *dysfunction*.
- 312
- 313 Imaging data
- 314
- 315 Subject head-motion was assessed and no subjects were excluded on this basis. There were 316 also no significant differences in head-motion between groups or across study visits; see 317 supplementary material for full details. Results of an analysis modelling the mean task 318 activation of all subjects from each group and all scan visits showed the predicted pattern of 319 task effects, with the emotional faces activating a broad pattern of brain regions including 320 primary and secondary visual cortex, amygdala, thalamus, insula, and superior frontal 321 regions (see supplementary figure S1). This pattern is entirely consistent with previous work 322 (e.g. ⁵⁴) and therefore validates the experimental and analysis procedures.
- 323
- Results from the main analyses of treatment and drug group effects are shown in figure 3.
- 325 This is a complex effect that models the interaction between the (within-subject) pre- and
- 326 post-treatment factor and the (between-subjects) treatment group factor. The voxel-wise
- 327 analyses found a large network of areas in which there was a decreased BOLD response
- post-treatment in the escitalopram group, relative to the psilocybin group. Significant
- 329 clusters were evident in the dorsolateral pre-frontal cortex, supramarginal gyrus, mid-insula,330 and superior temporal lobe.
- 331
- Data was extracted from this set of clusters and plotted across all the stimulus conditions
 (figure 3, panels B-E). A mixed-model 2 (group) x 2 (visit) x 3 (facial expression) ANOVA
- showed a significant main effect of study visit (F[1,44] = 5.27, p = 0.027). There were also
- significant interactions between the treatment group and visit factors (F[1,44] = 10.83, p =
- 336 0.002), and the visit and facial expression factors (F[2,86] = 10.09, p < 0.001).
- 337

338 Follow-up comparisons revealed that in the escitalopram group there was a significant 339 reduction in responses on the second visit (six weeks) for all three individual facial 340 expressions: fear (t[20] = 2.82, p = 0.011), happy (t[20] = 3.79, p = 0.001), and neutral (t[20]341 = 2.25, p = 0.036). This effect is also significant when collapsing across all facial expressions 342 (t[29] = 3.16, p = 0.005). All these results survive a Bonferroni-corrected p threshold of 343 0.0125, except the neutral faces result. In the psilocybin group, similar comparisons showed 344 a significant increase in responses on the post-therapy visit for the neutral facial expressions 345 (t[24] = -3.17, p = 0.004). This neutral faces result for the psilocybin group survived the 346 corrected alpha threshold (p = 0.0125). There were no other significant effects. 347



Figure 3. Results from the main analysis. Panel A shows results of a voxel-wise (*Z*> 2.3, *p* < 0.05, corrected for multiple comparisons) analysis of an interaction effect between the two treatment groups and study visit (psilocybin (pre- > post-

352 treatment) > escitalopram (pre- > post-treatment), showing a relatively greater 353 activation to faces in the post-treatment scan (relative to the pre-treatment baseline 354 scan) for the psilocybin group, compared with the escitalopram group. Panels B-E 355 break down this high-level effect and plot ROI data from this total set of clusters for 356 all task conditions, groups, and study visits. Results show that the effect is driven by 357 a decrease in response to all face types in the escitalopram group in the post-358 treatment visit, with minimal post-treatment change in the psilocybin group. In fact, 359 for neutral faces there is an increased activation post-treatment with psilocybin. * = 360 p < 0.05, see text for exact values.

361

Figure 4 shows the results of the analyses using a bilateral amygdala mask. These analyses compared pre- vs. post-treatment effects for the various task contrasts within each group

364 and found a significant activation cluster in the right amygdala for the escitalopram group,

- 365 with a smaller cluster in the right amygdala for the psilocybin group, both on the task
- 366 contrast of fear > neutral faces (figure 3, panels A and C). There were no other significant
- 367 effects on the other task contrasts conducted in these analyses using the amygdala mask.
- 368 Extracting and plotting data from the relevant activation clusters (figure 3; panels B and D),
- 369 and comparing baseline to post-therapy responses found that there was no change in the
- 370 psilocybin group post-treatment, however, there was a reduction in responses in the
- escitalopram group, with a significant effect for the fear faces (t[20]=2.33, p=0.031).
- 372 However, this effect does not survive a multiple-comparisons correction for the four tests
- 373 conducted here.
- 374



- 385 Reassuringly, in the control analysis of the pre-treatment (baseline) scans, BOLD activations 386 were not significantly different between the two groups on any task condition or contrast. 387
- 388

- 389 Relationships between BOLD and clinical data
- 390
- 391 Exploratory analyses were conducted to examine relationships between the ROI data
- 392 plotted in figure 2 and the selected clinical data presented in figure 1. Correlations were
- 393 calculated within each patient group comparing the change in clinical scores (i.e., score at
- 394 baseline, subtracted from the 6-week follow-up) with the change in BOLD activity (visit 1

subtracted from visit 2) from the regions identified in figure 2. There were no significant
 correlations present in these analyses. Results can be found in the supplementary material.
 397

- Additional exploratory work used two moderation analyses to test whether the change in brain activity (average of all faces) could predict the main clinical outcome (change in QIDS scores from baseline to six weeks), and whether this was moderated by emotional function (change in score on the LEIS). In the psilocybin group, the LEIS alone was significantly predictive of QIDS outcomes (Z = -2.24, p = 0.025), but brain activity alone was not (Z = -2.24, p = 0.025).
- 403 0.07, p = 0.944), and neither was the interaction between the predictor and moderator (Z = -
- 404 0.91, *p* = 0.363). For the escitalopram group, the change in brain activity was predictive of
- 405 BDI outcomes (Z = 1.97, *p* = 0.048), and while the LEIS alone was not (Z = 0.36, *p* = 0.721);
- 406 the interaction (i.e., a moderation of the predictive power of brain activity via LEIS) was
- 407 strongly significant (Z = 3.14, p = 0.002).
- 408
- 409 In moderation analyses, the interaction term is the most instructive result, and a significant
- 410 result denotes that the relationship between the predictor and the dependent variable is
- 411 stronger or weaker, given varying levels of the moderator. In this case, since all three
- 412 variables are negative (i.e. relative decreases in brain activity, decreases in depression, and
- 413 decreases in emotional function) it implies that in the escitalopram group the relationship
- 414 between brain function and the clinical outcome (QIDS) is stronger when patients have
- 415 greater levels of emotional blunting (i.e. lower scores on the LEIS). LEIS scores were
- relatively increased in the psilocybin group, meaning that the significant direct effect of the
- 417 LEIS on clinical outcome (Z = -2.24) implies that a higher level of emotional function post-
- 418 psilocybin-therapy relates to a greater post-treatment reduction in depression scores (i.e.
- 419 greater clinical effect) after the psilocybin-therapy. These analyses were also repeated with
- 420 the BDI as the dependent variable and showed a similar pattern of results; see
- 421 supplementary material.

Psilocybin group



Emotional function (LEIS) Z=0.36 p=0.721

423

424 Figure 5. Results of exploratory moderation analyses examining the effects of the 425 change in brain activity on the primary clinical outcome (QIDS) and its moderation by

426 a measure of emotional function (LEIS). In the psilocybin group (top) emotional

function has a significant effect on clinical outcomes, but there is no significant effect
of brain activity and no interaction effect. In the escitalopram group (bottom) the

429 change in brain activity has a robust effect on clinical outcome, and emotional

- 430 function also has a strong moderating effect, supporting mechanistic assumptions
- 431 about the action of the SSRI. Significant effects are denoted by a green arrow and *.

432 Discussion

433

434 Consistent with our primary hypothesis for this comparative mechanisms trial, we found 435 significant differences in brain responsiveness to emotional stimuli after escitalopram 436 compared with psilocybin for depression. The separate examination of treatment effects 437 revealed that the between-group differences were largely driven by decreases in 438 responsiveness post-treatment in the escitalopram group. Null, or opposite (i.e., slightly 439 increased activation) effects were seen in the psilocybin group, depending on the exact face 440 type i.e., increased activations post-treatment to neutral faces was seen in the whole brain 441 analysis. Results were generally consistent whether examining whole brain activations or 442 focusing specifically on the amygdala. Exploratory moderation analyses suggested that 443 outcomes were better predicted by the change in brain activity, moderated by changes in 444 emotional function, in the escitalopram group, whereas clinical outcomes were better 445 predicted by changes in emotional function in the psilocybin group. 446 447 This study's findings lend support to the view that psilocybin-therapy and SSRIs have distinct 448 therapeutic mechanisms of action ⁹. While both drugs act on the 5-HT system, SSRIs

increase synaptic concentrations of 5-HT by blocking its reuptake, whereas psilocybin

- 450 (through its main active metabolite, psilocin) acts as a direct agonist on certain 5-HT
- receptors, with a key action on the 5-HT2A receptor subtype ^{26,55}. Increased synaptic 5-HT
- via SSRIs should affect all available 5-HT receptors but there is some evidence to suggest
- 453 that the activation of inhibitory postsynaptic 5-HT1A receptors, which are heavily expressed
- 454 in limbic regions ⁵⁶ and implicated in emotional ⁵⁷ and sexual functioning ⁵⁸, play an

important role in the action of SSRIs. The four to six week lag in antidepressant effects withSSRIs is thought to be due to a gradual down-regulation of inhibitory 5-HT1A pre-synaptic

- 457 auto-receptors ⁵⁹, allowing a slow disinhibition of serotonergic efflux onto postsynaptic
- 458 targets. Although speculative, activating inhibitory postsynaptic 5-HT1A receptors in limbic
- 459 regions may dampen their responsiveness and account for the emotional blunting and loss
- 460 of sexual function described by some patients receiving treatment with SSRIs ⁷. The
- 461 moderation analyses provided here suggest that this reduction in brain responsiveness to
- 462 emotion with SSRIs may be an important factor in their therapeutic action.
- 463

464 The results of the whole-brain between-groups contrast revealed a pattern of reduced responsiveness under escitalopram in regions including the DLPFC, temporo-parietal 465 466 junction (TPJ), supramarginal gyrus, and secondary somatosensory cortex. These are largely high-level transmodal regions implicated in a broad range of processes, including social-467 468 cognitive functions. They are not necessarily regions most commonly identified in emotional face perception ⁵⁴, however, a recent meta-analysis ⁶⁰ highlighted a similar set of regions 469 470 involved in empathy for physical pain, emotional situations, and emotional faces. A further 471 recent meta-analysis of the neural effects of antidepressants as assessed by emotional 472 response paradigms has also identified effects in a wider set of cortical regions than just the

- 473 amygdala ¹⁰. Although speculative, the relative preservation of responsiveness in these high-
- 474 level cortical regions after psilocybin therapy may relate to its positive modulation of socio-
- 475 emotional functioning ⁶¹, an assumption that might also align with the greater
- 476 responsiveness to neutral faces post psilocybin therapy.
- 477

Psilocybin therapy is emerging as a potential paradigm-shifting^{62,63} treatment for depression 478 and other commonly comorbid disorders⁶⁴; paradigm-shifting because it is arguably the first 479 truly effective drug-assisted psychotherapy⁴¹. This may be because psilocybin enhances 480 481 affective psychotherapeutic processes in a different way to other compounds that have been combined with psychotherapy ⁶⁵ including SSRIs⁶⁶. Psilocybin therapy appears to have 482 an efficacy at least comparable to established treatments^{20,22,41}, with treatment response 483 rates of approximately 70% in three recent trials in MDD^{21,22,67}, and has a favorable side-484 485 effect and patient acceptance profile. The present finding of a robust difference in the 486 effects of an SSRI and psilocybin therapy on brain responsiveness to emotional stimuli are 487 consistent with previous assumptions about their differential therapeutic actions⁹, as well as

- 488 this trial's pre-registered primary mechanistic hypothesis
- 489 (https://clinicaltrials.gov/ct2/show/NCT03429075).
- 490
- 491 A generalized emotional blunting is often associated with SSRIs⁵, whereas greater
- 492 acceptance of emotions and a multi-faceted sense of reconnection^{39,68} is commonplace with
- 493 psilocybin-therapy. The differing pattern of effects in the exploratory moderation analyses
- 494 presented here also support this perspective. In the psilocybin group, the (relatively
- increased) emotional function was shown to have a direct positive effect on clinical
- 496 outcome, such that higher levels of emotional function were associated with greater
- 497 improvements in clinical symptoms. In the escitalopram group however, the effect of
- 498 changes in emotional function was a robust moderator of the effect of brain responses on
- the clinical outcome, but in an opposite direction. The relationship between brain function
- 500 (decreased responsiveness to faces) and clinical effects (decreased symptom severity) was
- 501 strongest for those patients who reported the largest muting of the intensity of their
- emotions (LEIS). As others have recently noted^{9,16} this emotional blunting associated with
 SSRIs may be a key factor in their therapeutic efficacy, and the current findings support this
- 504 perspective.
- 505
- The importance of the 5-HT2A receptor for the action of psychedelics is well established²⁶, as demonstrated for example, via a strong and selective affinity-to-potency relationship⁶⁹, antagonist pre-treatment blocking the psychedelic effects⁷⁰, and most recently, subjective psychedelic effects correlating with degree of 5-HT2A receptor occupation in the human brain⁷¹. 5-HT2A receptors are highly expressed throughout the human cortex^{56,72}, but particularly in high-level associative/transmodal regions that undergo marked expansion
- 512 throughout brain development⁷³ and have expanded most evolutionarily^{74,75}. A growing
- 513 body of evidence has linked 5-HT2A receptor signaling with increases in a variety of markers

of neuroplasticity^{76,77}. The most recent model of psychedelic therapy's mechanism of action 514 emphasizes a role for enhanced 5-HT2AR-induced cortical plasticity; opening a window for 515 healthy psychological change, guided by concomitant psychotherapy^{64,78}. In contrast to the 516 effects of SSRIs, suppressed emotional or limbic responsiveness is not a feature of the 517 psychedelic therapy model. Indeed, acute emotional release during 'the trip'⁷⁹ and then 518 progress towards greater emotional acceptance and 'reconnection'³⁹ are thought to be 519 520 important components of the psychedelic therapy model. Together with the present results, 521 replicated findings of increased whole brain functional integrity after psilocybin therapy for 522 depression ³⁰, as well as increased dynamic flexibility ²⁹, imply a different antidepressant 523 action for psilocybin relative to SSRIs.

524

Regarding this study's design, it should be noted that the final post-treatment scan occurred 525 526 hours after the final dose for those in the escitalopram group (coinciding with peak plasma 527 concentration of the drug) but three weeks after the second of two 25mg psilocybin 528 sessions for the psilocybin group. The smaller changes in post-treatment brain functioning in 529 the psilocybin group may be due to the duration since dosing and a different result may 530 have been found had we scanned closer to the last psilocybin dosing session, as we did in 531 previous work, where we showed a relative increases in amygdala responses one-day postdosing ²⁸. We believe that the present study's design can be justified however, as the 532 533 intention was to capture the enduring antidepressant effects of psilocybin-therapy, and these were robust at the 6-week endpoint (3 weeks after the final psilocybin dosing 534 535 session)⁴¹. Our current findings can be seen as consistent with previous work in which 536 healthy volunteers received a single-dose of psilocybin and reduced amygdala responses 537 were observed at a one-week follow-up, with responses returning to baseline after one 538 month ⁸⁰. Interestingly, a distinct metric (whole-brain network modularity applied to 539 spontaneous brain activity) has been found to reliably index the antidepressant action of 540 psilocybin-therapy, but not escitalopram³⁰. The implication is that (unlike for SSRIs¹¹) the 541 emotional face paradigm may not be an especially sensitive marker of the antidepressant 542 action of psilocybin-therapy (on this time-scale), whereas other brain indices may be more 543 sensitive to its specific action.

544

545 Some previous work has suggested that SSRIs and related antidepressant drugs have a 546 selective action on the processing of negatively valenced emotional stimuli ¹². We did not 547 replicate this result in the whole-brain analysis but we did see suggestions of less 548 suppression of amygdala responses to happy and neutral faces with escitalopram relative to 549 its effect on fearful faces. However, consistent with observations from previous work ^{81,82}, 550 faces of a negative valence evoked the largest amygdala responses in this study (figure 3). In 551 alignment with statistical principles, one could suggest that a drug's modulatory action 552 would be greatest in the domain of functioning that is especially sensitive under baseline 553 conditions, i.e. in this case, the negatively-valenced domain. It seems plausible therefore

- that this could account for SSRI's apparent biased action on negatively-valenced emotional
- 555 stimuli as seen in previous studies ¹².
- 556
- 557 In conclusion, consistent with the primary hypothesis for this trial, fMRI analyses revealed a
- reduced brain responsiveness to emotional face stimuli after six weeks of daily escitalopram
- 559 but not three weeks after the second of two 25mg dosing sessions with psilocybin-therapy
- 560 for major depressive disorder. The escitalopram data is consistent with current theories on
- the therapeutic action of SSRIs ¹⁵ and the comparison with psilocybin-therapy highlights the
- 562 different brain actions of these two different treatment modalities.

563 564	Re	References				
565 566	1.	Malhi GS, Mann JJ. Depression. <i>The Lancet</i> . 2018;392(10161):2299-2312. doi:10.1016/S0140-6736(18)31948-2				
567 568	2.	Davidson JRT. Major Depressive Disorder Treatment Guidelines in America and Europe. <i>The Journal of Clinical Psychiatry</i> . 2010;71(suppl E1). doi:10.4088/jcp.9058se1c.04gry				
569 570 571 572	3.	Cipriani A, Furukawa TA, Salanti G, et al. Comparative Efficacy and Acceptability of 21 Antidepressant Drugs for the Acute Treatment of Adults With Major Depressive Disorder: A Systematic Review and Network Meta-Analysis. <i>Focus</i> . 2018;16(4):420-429. doi:10.1176/appi.focus.16407				
573 574 575	4.	Machado M, Iskedjian M, Ruiz I, Einarson TR. Remission, dropouts, and adverse drug reaction rates in major depressive disorder: a meta-analysis of head-to-head trials. <i>Curr Med Res Opin</i> . 2006;22(9):1825-1837. doi:10.1185/030079906X132415				
576 577 578	5.	Goodwin GM, Price J, De Bodinat C, Laredo J. Emotional blunting with antidepressant treatments: A survey among depressed patients. <i>Journal of Affective Disorders</i> . 2017;221(June):31-35. doi:10.1016/j.jad.2017.05.048				
579 580 581	6.	Opbroek A, Delgado PL, Laukes C, et al. Emotional blunting associated with SSRI-induced sexual dysfunction. Do SSRIs inhibit emotional responses? <i>International Journal of Neuropsychopharmacology</i> . 2002;5(2):147-151. doi:10.1017/S1461145702002870				
582 583	7.	Cascade E, Kalali AH, Kennedy SH. Real-world data on SSRI antidepressant side effects. <i>Psychiatry</i> . 2009;6(2):16. Accessed March 26, 2021. www.iGuard.org				
584 585 586 587	8.	Cao B, Zhu J, Zuckerman H, et al. Pharmacological interventions targeting anhedonia in patients with major depressive disorder: A systematic review. <i>Progress in Neuro-Psychopharmacology and Biological Psychiatry</i> . 2019;92(December 2018):109-117. doi:10.1016/j.pnpbp.2019.01.002				
588 589	9.	Carhart-Harris RL, Nutt DJ. Serotonin and brain function: A tale of two receptors. <i>Journal of Psychopharmacology</i> . 2017;31(9):1091-1120. doi:10.1177/0269881117725915				
590 591	10.	Ma Y. Neuropsychological mechanism underlying antidepressant effect: A systematic meta-analysis. <i>Molecular Psychiatry</i> . 2015;20(3):311-319. doi:10.1038/mp.2014.24				
592 593 594	11.	Godlewska BR, Norbury R, Selvaraj S, Cowen PJ, Harmer CJ. Short-term SSRI treatment normalises amygdala hyperactivity in depressed patients. <i>Psychological Medicine</i> . 2012;42(12):2609-2617. doi:10.1017/S0033291712000591				
595 596 597	12.	Godlewska BR, Browning M, Norbury R, Cowen PJ, Harmer CJ. Early changes in emotional processing as a marker of clinical response to SSRI treatment in depression. <i>Translational Psychiatry</i> . 2016;6(11):1-7. doi:10.1038/tp.2016.130				

- 598 13. Maron E, Wall M, Norbury R, et al. Effect of short-term escitalopram treatment on
 599 neural activation during emotional processing. *Journal of Psychopharmacology*.
 600 2016;30(1):33-39. doi:10.1177/0269881115620462
- 4. McCabe C, Mishor Z, Cowen PJ, Harmer CJ. Diminished Neural Processing of Aversive
 and Rewarding Stimuli During Selective Serotonin Reuptake Inhibitor Treatment. *Biological Psychiatry*. 2010;67(5):439-445. doi:10.1016/j.biopsych.2009.11.001
- Harmer CJ, Duman RS, Cowen PJ. How do antidepressants work? New perspectives for
 refining future treatment approaches. *The Lancet Psychiatry*. 2017;4(5):409-418.
 doi:10.1016/S2215-0366(17)30015-9
- 16. Langley C, Armand S, Luo Q, et al. Chronic escitalopram in healthy volunteers has
 specific effects on reinforcement sensitivity: a double-blind, placebo-controlled semirandomised study. *Neuropsychopharmacol*. Published online January 23, 2023:1-7.
 doi:10.1038/s41386-022-01523-x
- 611 17. Nutt D, Erritzoe D, Carhart-Harris R. Psychedelic Psychiatry's Brave New World. *Cell*.
 612 2020;181(1):24-28. doi:10.1016/j.cell.2020.03.020
- 613 18. Carhart-Harris RL, Goodwin GM. The Therapeutic Potential of Psychedelic Drugs: Past,
 614 Present, and Future. *Neuropsychopharmacology*. 2017;42(11):2105-2113.
 615 doi:10.1038/npp.2017.84
- 616 19. Krystal JH, Abdallah CG, Sanacora G, Charney DS, Duman RS. Ketamine: A Paradigm Shift
 617 for Depression Research and Treatment. *Neuron*. 2019;101(5):774-778.
 618 doi:10.1016/j.neuron.2019.02.005
- 619 20. Carhart-Harris RL, Bolstridge M, Rucker J, et al. Psilocybin with psychological support for
 620 treatment-resistant depression: an open-label feasibility study. *The Lancet Psychiatry*.
 621 2016;3(7):619-627. doi:10.1016/S2215-0366(16)30065-7
- 622 21. Carhart-Harris R, Giribaldi B, Watts R, et al. Trial of Psilocybin versus Escitalopram for
 623 Depression. *New England Journal of Medicine*. 2021;384(15):1402-1411.
 624 doi:10.1056/nejmoa2032994
- 22. Davis AK, Barrett FS, May DG, et al. Effects of Psilocybin-Assisted Therapy on Major
 Depressive Disorder: A Randomized Clinical Trial. *JAMA Psychiatry*. Published online
 2020:1-9. doi:10.1001/jamapsychiatry.2020.3285
- 628 23. Griffiths RR, Johnson MW, Carducci MA, et al. Psilocybin produces substantial and
 629 sustained decreases in depression and anxiety in patients with life-threatening cancer: A
 630 randomized double-blind trial. *Journal of Psychopharmacology*. 2016;30(12):1181-1197.
 631 doi:10.1177/0269881116675513
- 632 24. Ross S, Bossis A, Guss J, et al. Rapid and sustained symptom reduction following
 633 psilocybin treatment for anxiety and depression in patients with life-threatening cancer:
 634 A randomized controlled trial. *Journal of Psychopharmacology*. 2016;30(12):1165-1180.
 635 doi:10.1177/0269881116675512

- 636 25. Grob CS, Danforth AL, Chopra GS, et al. Pilot study of psilocybin treatment for anxiety in
 637 patients with advanced-stage cancer. *Archives of General Psychiatry*. 2011;68(1):71-78.
 638 doi:10.1001/archgenpsychiatry.2010.116
- 639 26. Nichols DE. Psychedelics. 2016;(April):264-355.
- 640 27. Carhart-Harris RL, Erritzoe D, Williams T, et al. Neural correlates of the psychedelic state
 641 as determined by fMRI studies with psilocybin. *Proceedings of the National Academy of*642 *Sciences of the United States of America*. 2012;109(6):2138-2143.
- 643 doi:10.1073/pnas.1119598109
- 644 28. Carhart-Harris RL, Roseman L, Bolstridge M, et al. Psilocybin for treatment-resistant
 645 depression: fMRI-measured brain mechanisms. *Scientific Reports*. 2017;7(1):13187.
 646 doi:10.1038/s41598-017-13282-7
- 647 29. Doss MK, Považan M, Rosenberg MD, et al. Psilocybin therapy increases cognitive and
 648 neural flexibility in patients with major depressive disorder. *Translational Psychiatry*.
 649 2021;11(1):1-10. doi:10.1038/s41398-021-01706-y
- 30. Daws RE, Timmermann C, Giribaldi B, et al. Increased global integration in the brain
 after psilocybin therapy for depression. *Nature Medicine*. Published online 2022.
 doi:10.1038/s41591-022-01744-z
- 31. McCulloch DEW, Madsen MK, Stenbæk DS, et al. Lasting effects of a single psilocybin
 dose on resting-state functional connectivity in healthy individuals. *J Psychopharmacol*.
 2022;36(1):74-84. doi:10.1177/02698811211026454
- 32. Pasquini L, Palhano-Fontes F, Araujo DB. Subacute effects of the psychedelic ayahuasca
 on the salience and default mode networks. *J Psychopharmacol*. 2020;34(6):623-635.
 doi:10.1177/0269881120909409
- 33. Watts R, Luoma JB. The use of the psychological flexibility model to support psychedelic
 assisted therapy. *Journal of Contextual Behavioral Science*. 2020;15(April 2019):92-102.
 doi:10.1016/j.jcbs.2019.12.004
- Groenewold NA, Opmeer EM, de Jonge P, Aleman A, Costafreda SG. Emotional valence
 modulates brain functional abnormalities in depression: Evidence from a meta-analysis
 of fMRI studies. *Neuroscience & Biobehavioral Reviews*. 2013;37(2):152-163.
 doi:10.1016/j.neubiorev.2012.11.015
- 35. Roseman L, Demetriou L, Wall MB, Nutt DJ, Carhart-Harris RL. Increased amygdala
 responses to emotional faces after psilocybin for treatment-resistant depression. *Neuropharmacology*. 2018.
- 36. Majić T, Schmidt TT, Gallinat J. Peak experiences and the afterglow phenomenon: When
 and how do therapeutic effects of hallucinogens depend on psychedelic experiences?
 Journal of Psychopharmacology. 2015;29(3):241-253. doi:10.1177/0269881114568040

- 37. Murphy SE, Norbury R, O'Sullivan U, Cowen PJ, Harmer CJ. Effect of a single dose of
 citalopram on amygdala response to emotional faces. *The British journal of psychiatry : the journal of mental science*. 2009;194(6):535-540. doi:10.1192/bjp.bp.108.056093
- 38. Mertens LJ, Wall MB, Roseman L, Demetriou L, Nutt DJ, Carhart-Harris RL. Therapeutic
 mechanisms of psilocybin: Changes in amygdala and prefrontal functional connectivity
 during emotional processing after psilocybin for treatment-resistant depression. *Journal*
- 678 *of Psychopharmacology*. Published online 2020:1-14. doi:10.1177/0269881119895520
- 39. Watts R, Day C, Krzanowski J, Nutt D, Carhart-Harris R. Patients' Accounts of Increased
 "Connectedness" and "Acceptance" After Psilocybin for Treatment-Resistant
 Depression. *Journal of Humanistic Psychology*. 2017;57(5):520-564.
 doi:10.1177/0022167817709585
- 40. Cipriani A, Santilli C, Furukawa TA, et al. Escitalopram versus other antidepressive agents
 for depression. *Cochrane Database of Systematic Reviews*. 2009;(2).
 doi:10.1002/14651858.CD006532.pub2
- 41. Carhart-Harris R, Giribaldi B, Watts R, et al. Trial of Psilocybin versus Escitalopram for
 Depression. *New England Journal of Medicine*. 2021;384(15):1402-1411.
 doi:10.1056/nejmoa2032994
- 42. Rush AJ, Trivedi MH, Ibrahim HM, et al. The 16-item Quick Inventory of Depressive
 Symptomatology (QIDS), clinician rating (QIDS-C), and self-report (QIDS-SR): A
 psychometric evaluation in patients with chronic major depression. *Biological Psychiatry*. 2003;54(5):573-583. doi:10.1016/S0006-3223(02)01866-8
- 43. Beck AT, Steer RA, Carbin MG. Psychometric properties of the Beck Depression
 Inventory: Twenty-five years of evaluation. *Clinical Psychology Review*. 1988;8(1):77100. doi:10.1016/0272-7358(88)90050-5
- 44. Tennant R, Hiller L, Fishwick R, et al. The Warwick-Edinburgh Mental Well-being Scale
 (WEMWBS): development and UK validation. *Health and Quality of Life Outcomes*.
 2007;5(1):63. doi:10.1186/1477-7525-5-63
- 45. Snaith RP, Hamilton M, Morley S, Humayan A, Hargreaves D, Trigwell P. A scale for the
 assessment of hedonic tone the Snaith-Hamilton Pleasure Scale. *Br J Psychiatry*.
 1995;167(1):99-103. doi:10.1192/bjp.167.1.99
- 46. Montejo AL, García M, Espada M, Rico-Villademoros F, Llorca G, Izquierdo JA.
 [Psychometric characteristics of the psychotropic-related sexual dysfunction questionnaire. Spanish work group for the study of psychotropic-related sexual dysfunctions]. *Actas Esp Psiquiatr*. 2000;28(3):141-150.
- 47. Goeleven E, De Raedt R, Leyman L, Verschuere B. The Karolinska Directed Emotional
 Faces: A validation study. *Cognition & Emotion*. 2008;22(6):1094-1118.
 doi:10.1080/02699930701626582

- 48. Jack CR, Bernstein MA, Fox NC, et al. The Alzheimer's Disease Neuroimaging Initiative
 (ADNI): MRI methods. *Journal of Magnetic Resonance Imaging*. 2008;27(4):685-691.
 doi:10.1002/jmri.21049
- 49. Cauley SF, Polimeni JR, Bhat H, Wald LL, Setsompop K. Interslice leakage artifact
 reduction technique for simultaneous multislice acquisitions. *Magnetic Resonance in Medicine*. 2014;72(1):93-102. doi:10.1002/mrm.24898
- 50. Setsompop K, Gagoski BA, Polimeni JR, Witzel T, Wedeen VJ, Wald LL. Blipped-controlled
 aliasing in parallel imaging for simultaneous multislice echo planar imaging with reduced
 g-factor penalty. *Magnetic Resonance in Medicine*. 2012;67(5):1210-1224.
 doi:10.1002/mrm.23097
- 51. Xu J, Moeller S, Auerbach EJ, et al. Evaluation of slice accelerations using multiband echo
 planar imaging at 3T. *NeuroImage*. 2013;83:991-1001.
 doi:10.1016/j.neuroimage.2013.07.055
- 52. Demetriou L, Kowalczyk OS, Tyson G, Bello T, Newbould RD, Wall MB. A comprehensive
 evaluation of increasing temporal resolution with multiband-accelerated sequences and
 their effects on statistical outcome measures in fMRI. *NeuroImage*. 2018;176:404-416.
- 53. Smith SM, Jenkinson M, Woolrich MW, et al. Advances in functional and structural MR
 image analysis and implementation as FSL. *Neuroimage*. 2004;23:S208-S219.
- 54. Fusar-Poli P, Placentino A, Carletti F, et al. Functional atlas of emotional faces
 processing: a voxel-based meta-analysis of 105 functional magnetic resonance imaging
 studies. *Journal of psychiatry & neuroscience : JPN*. 2009;34(6):418-432.
- 55. McClure-Begley TD, Roth BL. The promises and perils of psychedelic pharmacology for
 psychiatry. *Nature reviews Drug discovery*. Published online 2022. doi:10.1038/s41573022-00421-7
- 56. Beliveau V, Ganz M, Feng XL, et al. A High-Resolution In Vivo Atlas of the Human Brain's
 Serotonin System. Published online 2017. doi:10.1523/JNEUROSCI.2830-16.2016
- 57. Phan KL, Wager T, Taylor SF, Liberzon I. Functional neuroanatomy of emotion: a metaanalysis of emotion activation studies in PET and fMRI. *NeuroImage*. 2002;16(2):331348. doi:10.1006/nimg.2002.1087
- 58. Comninos AN, Wall MB, Demetriou L, et al. Kisspeptin modulates sexual and emotional
 brain processing in humans. *Journal of Clinical Investigation*. 2017;127(2):709-719.
- 59. Celada P, Puig MV, Amargós-Bosch M, Adell A, Artigas F. The therapeutic role of 5-HT1A
 and 5-HT2A receptors in depression. In: *Journal of Psychiatry and Neuroscience*. Vol 29.
 Canadian Medical Association; 2004:252-265. Accessed March 29, 2021.
 /pmc/articles/PMC446220/
- 60. Ding R, Ren J, Li S, Zhu X, Zhang K, Luo W. Domain-general and domain-preferential
 neural correlates underlying empathy towards physical pain, emotional situation and

- emotional faces: An ALE meta-analysis. *Neuropsychologia*. 2020;137:107286.
 doi:10.1016/j.neuropsychologia.2019.107286
- 748 61. Preller KH, Pokorny T, Hock A, et al. Effects of serotonin 2A/1A receptor stimulation on
 749 social exclusion processing. *Proceedings of the National Academy of Sciences of the*750 *United States of America*. 2016;113(18):5119-5124. doi:10.1073/pnas.1524187113
- 62. Schenberg EE. Psychedelic-assisted psychotherapy: A paradigm shift in psychiatric
 research and development. *Frontiers in Pharmacology*. 2018;9(JUL):1-11.
 doi:10.3389/fphar.2018.00733
- 63. Carhart-Harris RL. Translational Challenges in Psychedelic Medicine. *N Engl J Med*.
 2023;388(5):476-477. doi:10.1056/NEJMcibr2213109
- 64. Carhart-Harris RL, Chandaria S, Erritzoe DE, et al. Canalization and plasticity in
 psychopathology. *Neuropharmacology*. 2023;226:109398.
 doi:10.1016/j.neuropharm.2022.109398
- 65. G. Hofmann S, T. Sawyer A, Asnaani A. D-Cycloserine as an Augmentation Strategy for
 Cognitive Behavioral Therapy for Anxiety Disorders: An Update. *Current Pharmaceutical Design*. 2012;18(35):5659-5662. doi:10.2174/138161212803530916
- 66. March JS. Fluoxetine, cognitive-behavioral therapy, and their combination for
 adolescents with depression: Treatment for Adolescents with Depression Study (TADS)
 randomized controlled trial. *Journal of the American Medical Association*.
 2004;292(7):807-820. doi:10.1001/jama.292.7.807
- Find Stock and St
- 68. Watts R, Kettner H, Geerts D, et al. The Watts Connectedness Scale: a new scale for
 measuring a sense of connectedness to self, others, and world. *Psychopharmacology*.
 Published online August 8, 2022. doi:10.1007/s00213-022-06187-5
- 69. Glennon RA, Titeler M, McKenney JD. Evidence for 5-HT2 involvement in the mechanism
 of action of hallucinogenic agents. *Life Sciences*. 1984;35(25):2505-2511.
 doi:10.1016/0024-3205(84)90436-3
- 776 70. Vollenweider FX, Vollenweider-Scherpenhuyzen MFI, Bäbler A, Vogel H, Hell D.
 777 Psilocybin induces schizophrenia-like psychosis in humans via a serotonin-2 agonist
 778 action. *NeuroReport*. 1998;9(17):3897-3902. doi:10.1097/00001756-199812010-00024
- 779 71. Madsen MK, Fisher PM, Burmester D, et al. Psychedelic effects of psilocybin correlate
 780 with serotonin 2 A receptor occupancy and plasma psilocin levels.
 781 Neuropsychology and plasma psilocin levels.
- 781 *Neuropsychopharmacology*. Published online 2019. doi:10.1038/s41386-019-0324-9

782 72. Erritzoe D, Ashok AH, Searle GE, et al. Serotonin release measured in the human brain: a 783 PET study with [11C]CIMBI-36 and d-amphetamine challenge. 784 Neuropsychopharmacology. 2020;45(5):804-810. doi:10.1038/s41386-019-0567-5 73. Hill J, Inder T, Neil J, Dierker D, Harwell J, Van Essen D. Similar patterns of cortical 785 786 expansion during human development and evolution. Proceedings of the National 787 Academy of Sciences of the United States of America. 2010;107(29):13135-13140. 788 doi:10.1073/pnas.1001229107 789 74. Rilling JK. Comparative primate neuroimaging: Insights into human brain evolution. 790 Trends in Cognitive Sciences. 2014;18(1):46-55. doi:10.1016/j.tics.2013.09.013 791 75. Van Essen DC, Dierker DL. Surface-based and probabilistic atlases of primate cerebral 792 cortex. Neuron. 2007;56(2):209-225. doi:10.1016/j.neuron.2007.10.015 793 76. Ly C, Greb AC, Cameron LP, et al. Psychedelics Promote Structural and Functional Neural 794 Plasticity. Cell Reports. 2018;23(11):3170-3182. doi:10.1016/j.celrep.2018.05.022 795 77. Vaidya VA, Marek GJ, Aghajanian GK, Duman RS. 5-HT(2A) receptor-mediated regulation 796 of brain-derived neurotrophic factor mRNA in the hippocampus and the neocortex. 797 Journal of Neuroscience. 1997;17(8):2785-2795. doi:10.1523/jneurosci.17-08-798 02785.1997 799 78. Carhart-Harris RL. How do psychedelics work? *Current opinion in psychiatry*. 800 2019;32(1):16-21. doi:10.1097/YCO.000000000000467 801 79. Roseman L, Haijen E, Idialu-Ikato K, Kaelen M, Watts R, Carhart-Harris R. Emotional 802 breakthrough and psychedelics: Validation of the Emotional Breakthrough Inventory. 803 Journal of Psychopharmacology. 2019;33(9):1076-1087. 804 doi:10.1177/0269881119855974 805 80. Barrett FS, Doss MK, Sepeda ND, Pekar JJ, Griffiths RR. Emotions and brain function are 806 altered up to one month after a single high dose of psilocybin. Scientific Reports. 807 2020;10(1):1-14. doi:10.1038/s41598-020-59282-y 808 81. Zald DH. The human amygdala and the emotional evaluation of sensory stimuli. Brain 809 research Brain research reviews. 2003;41(1):88-123. 82. Todorov A. The role of the amygdala in face perception and evaluation. *Motiv Emot*. 810 2012;36(1):16-26. doi:10.1007/s11031-011-9238-5 811

813 Supplementary material

814

815 Head movement

816

817 Overall head-motion characteristics for all subjects were excellent. Assessment of subject

- 818 head-motion during the scans was performed using the displacement time-series produced
- 819 during preprocessing of the functional data. These were collated, and means were
- 820 calculated across the time-series and across the six (three translations, three rotations)
- 821 displacement parameters. Maximum displacement values were also assessed.
- 822
- 823 Only one subject showed a maximum displacement value greater than one voxel dimension
- 824 (3mm) on a single parameter, for one study visit. Inspection of this subject's time series
- showed a single large (~3mm) shift in position part-way through the scan. This subject's
- mean displacement (0.088mm) was less than 0.1mm, and was comparable to other subjects
- in the sample. It was therefore judged to be acceptable, and the subject was included in the
- 828 analyses. Mean displacement across all subjects, scan sessions, and parameters was -
- 829 0.00058mm (SD = 0.027mm).
- 830
- A 2 (treatment group) by 2 (study visit) mixed-model ANOVA was conducted to examine any
- 832 systematic differences in head-motion across these factors. There was no main effect of
- treatment group (F[1,44] = 1.84, p = 0.182) and no main effect of study visit (F[1,44] = 0.11,
- 834 p = 0.740. There was also no interaction effect (F[1,44] = 0.077, p = 0.782).
- 835
- 836
- 837

838 Group-level task results





841 Figure S1. Results from the validation analyses of mean task effects in each group.

842

840

844 Correlation results

	Correlation of BOLD* data with:	Pearson's r	<i>p</i> value			
	Psilocybin group (N=25)					
	BDI change (baseline to six weeks)	0.132	0.529			
	WEMWBS change (baseline to 6 weeks)	-0.001	0.997			
	PRSEXDQ	-0.041	0.846			
	LEIS change (baseline to 6 weeks)	-0.07	0.762			
	SHAPS change (baseline to 6 weeks)	-0.001	0.998			
	QIDS change (baseline to 6 weeks)	0.084	0.718			
	Escitalopram group (N=21)					
	BDI change (baseline to six weeks)	0.075	0.748			
	WEMWBS change (baseline to 6 weeks)	-0.001	0.997			
	PRSEXDQ	-0.077	0.741			
	LEIS change (baseline to 6 weeks)	-0.022	0.927			
	SHAPS change (baseline to 6 weeks)	0.037	0.878			
	QIDS change (baseline to 6 weeks)	0.187	0.43			
846 847	*All faces vs. baseline contrast, pre-treatment vs. po	st-treatment				
848	Table S1. Correlation analyses between a summary measure of brain activity and key clinical					
849 850	measures. All analyses showed non-significant/n	ull results.				
851						
852						
853	Moderation Analyses with BDI as the depender	nt variable				
854						
855	The moderation analyses were repeated with BDI change scores (baseline to six-week					
856	follow-up) as the dependent variable. For the psilocybin group, this produced the same					
857	pattern of results as the analysis with QIDS scores in the main text. There was a significant (Z					
858	= -3.02, p = 0.003) effect of the LEIS measure on BDI scores, but no effect of brain activity (Z					
859	= -0.29, p = 0.774) and no interaction effect (Z = 1.32, p = 0.187). In the escitalopram group					
860	there were no main effects of either brain activity ($Z = 1.49$, $p = 0.137$) or LEIS ($Z = -0.59$, $p = 0.137$)					
861	0.551) on BDI change scores, but a significant interaction effect (Z = 2.38, p = 0.018).					